Actos Bladder Cancer Lawyers
Actos (pioglitazone) is an oral diabetes drug that has been linked to a higher incidence of bladder cancer. Approved by the FDA to treat Type 2 diabetes in 1999, Actos became a popular alternative to Avandia, another diabetes drug that has been linked to heart disease, strokes, and other health threats. Evidence from numerous recent studies has shown that Actos users face an increased risk of bladder cancer.
If you have developed bladder cancer after taking Actos, you may be entitled to pursue compensation in a dangerous medications lawsuit. Our experienced product liability attorneys are currently reviewing Actos bladder cancer lawsuit claims.
Call our product liability attorneys at 1-888-554-2889.
A free, no-obligation Actos lawsuit case evaluation
No fee unless we win your case
Helping Actos side effect victims Nationwide
Actos and Bladder Cancer
In September 2010 the FDA made public the launch of an investigation into the potential risk of bladder cancer for diabetes patients who take Actos. The FDA cited data from an ongoing study by Actos manufacturer Takeda Pharmaceuticals that suggests that the risk of Actos bladder cancer is heightened the longer a person uses the drug. This study is ongoing, and the FDA has yet to release any conclusions to the investigation.
An Italian study published in 2011 revealed a disproportionate number of Actos bladder cancer reports in the FDA Adverse Event Reporting System Records. However, this study did not effectively establish a causal relationship between Actos and bladder cancer.
In June, the FDA revised the Actos label to include bladder cancer warnings, informing Actos users that there is an increased risk of bladder cancer associated with this potentially dangerous drug. This risk is elevated when Actos is used for more than one year. Drugs similar to Actos, including Actoplus Met, ActoplusMet RX, and Duetact will also carry this warning.
European Actos Recalls
While Actos continues to be prescribed in the United States, a number of European countries have suspended sales of Actos pending further evaluation. German and French regulators announced a suspension of Actos in June. Since then, Takeda Pharmaceuticals issued an Actos recall in France following pressure from Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). A related drug, Campetact, sold as Actoplus Met in the U.S., will also be recalled in France.
Contact an Actos Bladder Cancer Lawyer
Our pharmaceutical product liability attorneys are dedicated to holding Takeda Pharmaceuticals accountable on behalf of Actos bladder cancer victims. If you or someone you love has been diagnosed with bladder cancer after taking Actos, you may be entitled to substantial compensation in an Actos bladder cancer lawsuit. Contact our personal injury lawyers today to schedule a free and confidential legal consultation.